Cabot scores 18x return on MedicX sale

Alice Murray
02 October 2014

Tweet
Facebook
LinkedIn
Google plus
Send to

Cabot Square Capital has sold healthcare investment manager MedicX Group to Octopus Investments, generating an 18x return on invested capital.

For Octopus, the deal has enabled the investor to scale up its healthcare business.

The firm completed the investment through its parent company Octopus Capital. The transaction takes Octopus's funds under management to £4.7m.

Cabot Square supported the creation of MedicX in 2004 in order to capitalise on the emergence of healthcare property as an institutional asset class.

Today, MedicX is a UK healthcare investment manager with £900m of funds under management across its LSE listed MedicX Fund (MXF) and two private closed-ended funds. The company also operates a proprietary origination platform, which develops healthcare properties for the funds it manages.

The company employs 30 people throughout the UK.

Keith Maddin is a partner at Cabot Square. Mike Adams is CEO of MedicX and David Staples is chairman of MedicX Fund. Simon Rogerson is CEO of Octopus.